Amarin jumps on MARINE data

Amarin Corp. plc (NASDAQ:AMRN) jumped $2.30 (65%) to $5.85 on Monday after reporting that twice-daily oral AMR101 met the primary endpoint of significantly reducing triglycerides from baseline to week 12 vs. placebo in the Phase III MARINE trial to treat hypertriglyceridemia. Specifically, low- and high-dose AMR101 reduced median triglyceride levels by 20% and 33% compared to placebo (p=0.0051 and p<0.0001, respectively). According to the trial's protocol, a p-value of 0.01 or less was required to achieve statistical significance on the endpoint. The double-blind, international trial enrolled 229 patients with fasting triglyceride levels of at least 500 mg/dL. ...